PhotoCure ASA (PhotoCure ASA) DeferredTaxAndRevenue : $0.00 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is PhotoCure ASA DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

PhotoCure ASA's current deferred tax and revenue for the quarter that ended in Mar. 2024 was $0.00 Mil.

PhotoCure ASA DeferredTaxAndRevenue Historical Data

The historical data trend for PhotoCure ASA's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhotoCure ASA DeferredTaxAndRevenue Chart

PhotoCure ASA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

DeferredTaxAndRevenue

Get a 7-Day Free Trial

PhotoCure ASA Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
DeferredTaxAndRevenue	Get a 7-Day Free Trial															-	-	-	-	-

PhotoCure ASA DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of PhotoCure ASA's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.

PhotoCure ASA (PhotoCure ASA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PhotoCure ASA (OTCPK:PHCUF) » Definitions » DeferredTaxAndRevenue

Comparable Companies

Traded in Other Exchanges

PHOO:Sweden PHO:Norway 0IMT:UK

Address

Hoffsveien 4, Oslo, NOR, 0275

Website

https://www.photocure.com

PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products specialty pharmaceutical companies. Its technology platform is focused on the field of photodynamic diagnosis and treatment of cancer. It has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, Netherlands, Other European countries, and the United States.